Synairgen (SNG.L) is up another 10% this morning after gaining 420.55% yesterday on the London Stock Exchange following the release of positive clinical trial results for their interferon inhalation device to treat COVID-19. Synairgen's market cap has just reached US$396.91 million, but we believe that a North American listed biotech company with similar interferon inhalation technology has a chance of surpassing Synairgen in market cap after they complete their own 150 patient clinical trials later this year: BetterLife Pharma (CSE: BETR) or BETRD in the U.S.
BETR at its current price of $2.35 per share has a market cap of only US$30 million. BETR has just issued a press release this morning entitled, 'Interferon Treatment Trial a Major Breakthrough Against the Pandemic'. Click here to read BETR's press release!
BETR has just announced in its press release that Synairgen's positive clinical trial results confirm the premise advocated by BETR suggesting that an interferon inhalation treatment for COVID-19 reduces the number of patients needing intensive care. Synairgen's interferon beta treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus. The initial findings suggest the treatment cut the odds of a COVID-19 patient in the hospital developing severe disease such as requiring ventilation by 79%!
The study reported "very significant" reductions in breathlessness among patients who received the treatment and highlighted how patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness.
The treatment in the study used interferon beta, as opposed to the patent-pending interferon alpha 2b (IFN-a2b) treatment developed by BETR called AP-003. Whether alpha or beta, both interferon proteins are produced when the body encounters a viral infection and act as antiviral agents, modulating functions of the immune system. Interferons were so named for their ability to “interfere” with viral replication by protecting cells from virus infections. IFN-a2b has been used with great success with other respiratory illnesses. Interferon treatments have been studied against coronaviruses including MERS-CoV, SARS-Cov-1 and now SARS-CoV-2 (the causative agent of COVID-19).
BETR began to breakout yesterday rallying by 24.34% to $2.35 per share on volume of 135,377 or 12.70X above average! Although BETR's volume yesterday was its highest of 2020, we look for BETR's volume to reach 500,000-1,000,000 shares in a day prior to the stock reaching a short-term peak. Right now, very few investors are aware of BETR outside of NIA's membership base, but we expect a much wider audience to learn about BETR beginning today!
BETR's chart is setup perfectly following yesterday's breakout from a pennant pattern!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from BETR of USD$50,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.